We are IntechOpen, the world’s leading publisher of Open Access books Built by scientists, for scientists

6,600 Open access books available
177,000 International authors and editors
195M Downloads

154 Countries delivered to
TOP 1% Our authors are among the most cited scientists
12.2% Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us? Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected. For more information visit www.intechopen.com
1. Introduction

Down Syndrome (DS) is one of the most common genetic disorders to date, occurring in 1 out of every 800-1000 live births (Egan et al. 2004; Roizen & Patterson, 2003; Stoll et al. 1990). DS patients often display several developmental and cognitive deficiencies. Common phenotypes of DS patients include congenital heart disease, dysmorphic physical features, and early-onset Alzheimer’s disease (AD). Since the discovery in 1959 that DS occurs from an extra copy of human chromosome 21 (hChr21) (Lejeune J, Gautier & Turpin, 1959), questions arose whether a 1.5-fold increase in a gene or set of genes were responsible for the phenotypes associated with DS. Sequence analysis of hChr21 identified over 225 genes and/or predicted genes (Hattori et al. 2000). With the recent advances in sequencing, the gene content of hChr21 is now estimated to exceed 300 genes (Roizen & Patterson, 2003). While typically characterized by complete trisomy of hChr21, several DS cases, however, demonstrate that partial trisomy of hChr21 is enough to elicit the phenotypes associated with DS (Stoll et al. 1990), hence arising the concept of a Down Syndrome Critical Region (DSCR). The DSCR theory suggests that enhanced expression of a few genes located in this critical chromosomal region (between markers D21S17 and D21S55 (Delabar et al. 1993; Korenberg et al. 1994)) are responsible for some, if not all, of the features of DS. Olson LE et al show, however, that triplication of this region alone is not enough to fully manifest the phenotypes associated with DS (Olson et al. 2004; Olson et al. 2007). These findings contradict the longstanding DSCR theory, indicating that the genetic instability seen with hChr21 triplication is not merely from excess gene expression. Rather, the functional interactions occurring within a set of overexpressed genes may explain the various phenotypes observed in DS. Many of the triplicate genes on hChr21 are implicated in several diseases. Cohorts of genes, interestingly, have been associated with pathologies that appear to be more common for DS individuals. A group of at least 16 genes on hChr21 have been correlated with a role in energy and reactive oxygen species (ROS) metabolism (Roizen & Patterson, 2003). Several studies have linked mitochondrial dysfunction and metabolic disorders with DS (Arbuzova, Hutchin & Cuckle, 2002). In vitro, DS neurons were observed to have 3- to 4-fold increases in reactive oxygen species compared to control cells, with elevated rates of consequent cell apoptosis (Busciglio & Yankner, 1995). Degeneration of DS neurons was rescued by administration of free-radical scavengers, suggesting DS neurons are unable to efficiently metabolize ROS. DS patients are also evidenced to have increased mitochondrial superoxide...
production compared to control groups (Capone et al. 2002). In addition, Busciglio J et al. show altered processing of the amyloid precursor protein (APP) in DS astrocytes and neurons (Busciglio et al. 2002). Elevated levels of APP, a gene also located on hChr21, have been associated with AD progression. Given that DS patients invariably display the characteristic plaques and tangles suggestive of AD (Hardy & Selkoe, 2002), this 1.5-fold increase in particular hChr21-located genes may explain the metabolic-related diseases associated with DS patients.

Another cohort of at least 10 genes located on hChr21 have been demonstrated to influence the central nervous system (CNS), and may hence play a role in the neuropathogenesis of DS (Capone, 2001). Considering the major phenotypes of DS patients include altered brain development, neuronal loss, and Alzheimer’s-like neuropathology, the identification of CNS-related genes is not surprising. As demonstrated by these two gene clusters, phenotypic outcome is dependent not only on genotype but also on successive protein interactions. It is therefore possible that additional sets of genes, when in excess as a result of trisomy hChr21, lead to the manifestation of other DS-related pathologies, such as vascular-related pathologies.

2. Clinical observations and chapter overview

While developmental and behavioral disorders have been extensively studied in adults with DS, relatively little is known regarding their propensity to vascular-related diseases. Several intriguing clinical observations relating to the vasculature have been reported amongst DS patients over the last several decades. Unlike the aforementioned developmental deficits of DS individuals, DS patients appear to have a unique advantage in the context of several vascular pathologies.

2.1 Cancer incidence in DS patients

While adults with DS have been shown to have a higher incidence of leukemia compared to the general public, the risk of solid tumors appear to be strikingly low in individuals with DS (Hasle, Clemmensen & Mikkelsen, 2000). A population-based study on causes of mortality in over 17,000 DS patients showed a significant lack of malignant neoplasms as a cause of death (Yang, Rasmussen & Friedman, 2002). These findings suggest that individuals with DS express possible tumor-suppressor genes on hChr21, such that trisomy of a set of genes results in an antineoplastic effect on solid tumors. It is possible that these set of genes modulate a common biological mechanism that is critical for tumorigenesis and/or cancer progression.

2.2 Atherosclerosis in DS patients

A post-mortem, observational study published in 1977 found that 40-66 year old patients with DS displayed an almost complete absence of atherosclerotic plaque formation in arteries, compared to those without DS (Murdoch et al. 1977). Additional population studies in DS patients have found consistent results (Draheim, Geijer & Dengel, 2010; Yla-Herttuala et al. 1989), leading one to speculate that an unidentified factor(s) specific to DS patients explains the near absence of atherosclerotic plaque formation. Considering the vascular similarities between tumorigenesis and atherosclerosis, it is possible these events are driven by a shared molecular mechanism.
2.3 Other vascular pathologies in DS patients

Studies focusing on vascular tone show that DS patients have extremely low percentages of hypertension (Kerins et al. 2008). Significant decreases in both systolic and diastolic pressures were observed in DS patients when compared to reference populations (Morrison et al. 1996; Richards & Enver, 1979). Low blood pressures have also been observed in Alzheimer’s disease (AD) (Burke et al. 1994; Landin et al. 1993), suggesting the mechanisms driving AD contribute to the observed hypotensive tendencies of DS patients. The already mentioned propensity for DS patients to develop AD, in addition to blood pressure levels similar to that of AD patients, strongly suggests a shared genetic contribution(s) of hChr21-located genes.

The observed decrease in solid tumor growth, lack of atherosclerotic plaque formation, and hypotensive nature of DS adults indicates onset of these vascular disorders may share an underlying molecular mechanism. This chapter will aim to discuss the observed differences in the vasculature of DS patients based on current literature to date. As of now, there is no concrete evidence distinguishing DS patients from non-DS patients on a genetic level concerning vascular anomalies. Correlative studies, however, suggest DS individuals harness a genetic advantage in regard to vascular health and disease.

3. Tumorigenesis in Down Syndrome

The molecular mechanisms underlying oncogenesis are undoubtedly one of the most intricate processes to date. Accumulation of multiple genomic mutations leads to the dysregulation of cell signaling pathways that are critical for controlling basic cellular functions including cell growth, survival, and cell fate. The extensive cross-talk between various signaling cascades highlights the sophisticated communication that transpires during cancer development and progression.

3.1 Calcium/calcineurin/NFAT signaling

Calcium (Ca$^{2+}$) fluxes are involved in multiple cell processes such as cell metabolism, membrane transport, cell permeability, and apoptosis. Changes in intracellular Ca$^{2+}$ levels affect downstream gene expression and cell function through various mechanisms. In particular, intracellular Ca$^{2+}$ concentrations often regulate kinase and phosphatase activity through the Ca$^{2+}$-binding protein, calmodulin (CaM). Increases in intracellular Ca$^{2+}$ have been demonstrated in various cell types to activate the Ca$^{2+}$/CaM-dependent serine-threonine protein phosphatase, calcineurin (Cn). The Cn pathway is critical for the transduction of many extracellular, adaptive stimuli. Activated Cn subsequently dephosphorylates target proteins, including the nuclear factor of activated T-cells (NFATc1-c4) family of transcription factors (Figure 1). The NFAT family was originally identified in lymphocytes for its role in cytokine gene expression. While first identified in immune cells, recent findings show NFAT proteins are ubiquitously expressed. NFAT at the basal state are localized to the cytoplasm in an inactive form, with more than 20 identified phosphorylation sites (Okamura et al. 2000). CaM/Cn-mediated dephosphorylation of NFAT promotes nuclear translocation and target gene transcription (Figure 1). As downstream effectors of the Cn signaling pathway, NFAT-dependent gene transcription influences a range of cellular functions, including endothelial cell migration (Minami et al. 2004), skeletal muscle differentiation (Rothermel et al. 2000), cardiac valve development (Lange, Molkentin & Yutzey, 2004), and vascular smooth muscle cell adaptation (Crabtree & Olson, 2002; Horsley & Pavlath, 2002; Lee et al. 2010).
Fig. 1. The Cn/NFAT signaling pathway. Calmodulin (CaM), calcineurin (Cn), cyclosporin A (CsA) (adapted from Viola, J.B.P., 2005)

Given the versatility of NFAT activation, it is not surprising that solid tumors and hematological malignancies are correlated with overexpression of NFATc isoforms. For example, pancreatic carcinomas display elevated levels of NFATc1 for transcriptional activation of the c-myc oncogene (Buchholz et al. 2006). Studies using human breast carcinoma cell lines also show NFATc2 expression promotes carcinoma migration and invasion (Jauliac et al. 2002). The increased NFATc activity in malignant cells suggests activation of downstream NFATc targets is critical for tumor progression. Cyclooxygenase-2 (COX2/PTGS2) has been reported by several groups as an NFAT-dependent gene in non-lymphoid tissues, including endothelial cells (Hernandez et al. 2001), mesangial cells (Sugimoto et al. 2001), and vascular smooth muscle cells (Pritchard, Jr. et al. 1994). As an enzyme involved in prostaglandin formation, COX2 expression plays an important role in cell survival and angiogenesis. A gain-of-function approach shows that forced overexpression of COX2 alone is enough to induce mammary gland tumorigenesis (Liu et al. 2001). On the converse, inhibition of COX2 significantly reduces colon tumor incidence and multiplicity in a dose-dependent manner (Reddy et al. 2000). These findings strongly support the notion that tumor growth/invasion necessitates an abundance of COX2 levels. The increased expression of COX2 in a multitude of cancer lines (i.e. gastric, esophageal, breast, bladder, cervical, colorectal, endometrial (Brown & DuBois, 2005; Duque, Fresno & Iniguez, 2005b)) have thus launched the production of several COX2 inhibitors with therapeutic potential. It is, however, important to note the importance of COX2 in other cell types. Unlike the constitutively expressed COX1 isoform, COX2 expression occurs in a
limited number of cell types, primarily in response to cytokines, inflammatory mediators, and tissue damage (Lipsky et al. 2000). The inducible nature of COX2 activation results in prostaglandin formation, including prostacyclin, a vasodilator and a potent inhibitor of platelet aggregation. Prostacyclin formation in vascular endothelial cells thus provides a mechanism by which the thrombotic response in platelet activation can be regulated (Rudic et al. 2005). Hence, COX2 expression is necessary to maintain vascular health. While COX2-selective inhibitors may attenuate tumor angiogenesis, COX2 antagonists will undoubtedly shift eicosanoid balance toward a prothrombotic state, promoting the risk for cardiovascular events (Mukherjee, Nissen & Topol, 2001). Targeting other proteins involved in Cn/NFAT signaling aside from COX2 may yield similar anti-neoplastic results. Tumor survival and growth is highly-dependent on a vascular system for delivery of essential nutrients and oxygen. A tumor’s vasculature also provides a mechanism by which aberrant cells can disseminate to other organs. Without a constant blood supply, tumor volumes tend to remain 1-2mm in size (Brown & DuBois, 2005). Angiogenesis is a multi-step process that involves migration, proliferation, and differentiation of both endothelial and vascular smooth muscle cells for generation of mature vessels. Tumor cells can facilitate an ‘angiogenic switch’ by altering gene transcription and the surrounding microenvironment. Somatic mutations of various proto-oncogenes and/or tumor suppressor genes offset the balance between activators and inhibitors of angiogenesis, ultimately favoring angiogenic activity (Hanahan & Weinberg, 2000). Pro-angiogenic gene expression is induced by a number of physiological stimuli, such as hypoxia. Cells in hypoxic conditions produce the hypoxia-inducible factor (HIF) transcription factor, where expression of HIF-1 results in Vascular Endothelial Growth Factor (VEGF) transcription (Forsythe et al. 1996). VEGF, a major stimulator of angiogenesis, is a potent endothelial mitogen involved in both physiological and pathological blood vessel formation. VEGF is critical for proper embryonic vasculogenesis, as even heterozygous VEGF-deficient mice display abnormal blood vessel formation and consequent embryonic lethality (Carmeliet et al. 1996). While necessary for proper blood vessel development, excess VEGF can result in pathological angiogenesis. HIF-1-mediated VEGF expression and activation of other angiogenesis-related genes exemplifies the adaptive responses seen in tumor survival and growth. VEGF has also been demonstrated to induce COX2 expression in a Cn/NFAT-dependent manner (Duque, Fresno & Iniguez, 2005c). As previously mentioned, COX2 expression is critical for tumor cell migration and tube formation. The emerging role of NFAT signaling in oncogenesis is further highlighted, as pharmacological inhibition of NFAT blocks VEGF-stimulated COX2 expression and subsequent cell proliferation and/or angiogenesis both in vitro and in vivo (Hernandez et al. 2001). These results imply activation of Cn/NFAT signaling is required for the formation of new blood vessels, where regulation of angiogenesis is dependent on a local balance between angiogenic factors and inhibitors. The identification of Cn/NFAT activators and downstream NFAT target genes in the last few decades has therefore helped elucidate the biological mechanisms underlying oncogenesis.

3.2 DSCR1 in cancer progression
Cancer incidence for all solid tumors and malignancies have been shown in multiple DS population studies to be significantly lower in DS patients compared to control groups (Hasle et al. 2000; Yang et al. 2002). Interestingly, a large focus has been placed on the role of the Down Syndrome Candidate Region 1 (DSCR1/RCAN1/MCIP1) gene in cancer
progression. Located on hChr21, DSCR1 has been demonstrated as a negative feedback regulator of Cn/NFAT signaling through physical binding to the catalytic subunit of Cn (Fuentes et al. 2000) (Figure 1). In endothelial cells, VEGF and thrombin stimulation dramatically upregulate DSCR1 expression in a Cn/NFAT dependent manner (Iizuka et al. 2004; Minami et al. 2004). Several studies in endothelial cells have shown that DSCR1 overexpression inhibits NFAT transcriptional activity, suppresses NFAT nuclear accumulation, and attenuates NFAT-dependent inflammatory marker gene expression, such as COX2 (Hesser et al. 2004; Yao & Duh, 2004). Studies also show DSCR1 overexpression in endothelial cells reduces vascular density in matrigel plugs in vitro and in tumor growth in mice (Minami et al. 2004). Lastly, functional data indicate constitutive expression of DSCR1 impairs endothelial cell proliferation and tube formation (Minami et al. 2004). Taken together, VEGF and thrombin-mediated endothelial cell proliferation/vascularization induces expression of DSCR1 as a mechanism to negatively regulate the angiogenic processes.

Researchers have attempted to explain the lack of tumorigenesis in the DS population through use of genetically modified mice. Comparative mapping between mice and humans identify that hChr21 is genetically homologous to mouse chromosome 16 (mChr16) (Reeves & Citron, 1994). Thus, mice exhibiting trisomy of mChr16 (Ts16) were originally developed to study DS. Ts16 mice, however, die in utero and therefore pose as a limitation. In addition, several genes located on mChr16 are found on human chromosomes other than hChr21. The observed embryonic lethality as well as gene dosage imbalances resulted in generation of the Ts65Dn mouse (Reeves et al. 1995). The Ts65Dn mouse model reflects partial trisomy of hChr21, where mice have been reported to display a variety of phenotypes, including behavioral abnormalities consistent with DS (Reeves et al. 1995). Ts65Dn mice are now widely used to study DS at all stages of development.

A recent publication highlights the suppression of tumor growth seen in DS individuals using two different models: 1) the Ts65Dn mouse and 2) a DSCR1-transgenic mouse. Ts65Dn mice possess extra genetic information including the DSCR1 gene – Ts65Dn mice exhibit a 1.7-fold increase in DSCR1 protein expression compared to diploid controls (Baek et al. 2009). Baek KH et al demonstrate that both lung carcinoma and melanoma cell growth was significantly suppressed in Ts65Dn mice, when compared to control groups (Baek et al. 2009). Under the transplantable tumor model, Ts65Dn mice also display significant decreases in tumor growth and microvessel density (Baek et al. 2009). Similar results were seen when using DSCR1-transgenic mice, suggesting that one extra copy of DSCR1 is sufficient for tumor growth suppression. Given that hChr21 contains over 200 genes, however, it is likely that other genes act in concert with DSCR1 to facilitate tumor suppressive effects. Another gene of interest includes Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase (DYRK1A), a nuclear serine/threonine kinase located on hChr21. DYRK1A phosphorylates several transcription factors including NFAT. DYRK1A can therefore reduce Cn/NFAT-dependent transcription through its ability to export nuclear NFAT. Baek KH et al also show that endothelial cells overexpressing DSCR1 together with DYRK1A demonstrate an even greater suppression of VEGF-mediated cell proliferation (Baek et al. 2009). Future work by Baek KH et al will focus on additional hChr21-located genes known to suppress tumor angiogenesis through alternate mechanisms (Ryeom, Baek & Zaslavsky, 2009), such as COLLAGEN XVIII (COL18A1), a precursor to the angiogenesis inhibitor endostatin, and ADAMTS1, a metalloproteinase known to regulate the anti-angiogenic function of thrombospondin-1 (Iruela-Arispe, Carpizo & Luque, 2003;
Zaslavsky et al. 2010). In summary, the tumorigenic protective effects seen in DS adults may be due to increased expression of select hChr21-located genes, including DSCR1.

4. Atherosclerosis in Down Syndrome

Atherosclerosis progression is a complex process involving several cell types, multiple biological mechanisms, and environmental factors. The pathogenesis of atherosclerotic plaque formation is highly dependent on hemodynamic flow patterns (DeBakey, Lawrie & Glaeser, 1985; Vanderlaan, Reardon & Getz, 2004), thrombotic processes, and inflammatory signaling cascades (Lusis, 2000). Atherosclerosis is one of the leading causes of mortality in Westernized societies, and thus several cardiovascular risk factors have been identified over the last few decades in an effort to predict cardiovascular events. Given that atherosclerosis is characterized by accumulation of lipids in the large arteries, it is not surprising that elevated plasma triglyceride levels have been demonstrated as a direct propagator of cardiovascular disease (Austin, Hokanson & Edwards, 1998; Hokanson & Austin, 1996). Other plasma measurements indicative of cardiovascular risk include reduced levels of high-density lipoprotein (HDL) (Assmann et al. 1996; Gordon et al. 1977), and elevated serum levels of C-reactive protein (CRP), an indicator of inflammation (Mendall et al. 1996). High values for body mass index have also been demonstrated as a measure of cardiovascular risk (Berenson et al. 1998).

Atherosclerotic cardiovascular disease has been associated with metabolic syndrome, which includes several clinical disorders such as obesity, insulin resistance, glucose intolerance, hypertension, and dyslipidemia (Moller & Kaufman, 2005). Consistent with the aforementioned metabolic deficiencies associated with DS patients, individuals with DS also exhibit impaired lipid metabolism (Ishihara et al. 2009). In addition, DS patients have lower levels of low-density lipoprotein receptor (LDLR) expression compared to adults without DS (Corsi et al. 2005). Interestingly, lack of or dysfunctional LDLR expression results in familial hypercholesterolemia, a genetic disease characterized by elevated cholesterol levels and premature coronary artery disease (Brown & Goldstein, 1976). LDLR-null mice have since been generated and is now a widely used atherosclerotic mouse model (Ishibashi et al. 1993; Wouters et al. 2005). Lastly, DS patients exhibit significantly elevated levels of plasma triglycerides, low levels of HDL, high levels of CRP, and high levels of total body fat (Corsi et al. 2005; Draheim et al. 2010; Nishida et al. 1977). Taken together, these findings imply DS adults are surely at risk for cardiovascular events. DS patients, however, are significantly less susceptible to cardiovascular disease. A comparison of intimal-to-medial thickness (IMT) of the common carotid artery in DS adults show significantly lower IMT ratios when compared to control groups (Draheim et al. 2010). These findings corroborate the observational findings in 1977 where DS patients were proposed to be an “atheroma-free model” (Murdoch et al. 1977). One can speculate that DS patients thus express an altered gene expression profile where an additional copy of hChr21-located genes results in protection against atheroma formation, despite the many validated plasma indicators of cardiovascular risk. Similar to the identified gene clusters responsible for the metabolic and developmental deficiencies in DS patients, it is highly likely that a cohort of genes located on hChr21 is responsible for the protective effects against cardiovascular disease. Identification of these genes will therefore provide a therapeutic direction as we continue to understand the etiology behind atherosclerotic plaque formation.
4.1 Vascular smooth muscle and atherogenesis

At the cellular level, atherosclerosis progression is characterized by lipid accumulation and fibrous lesion formation in large arteries, resulting in chronic arterial wall inflammation. The release of cytokines and growth factors induce vascular smooth muscle cells (SMC) to undergo a process known as phenotypic modulation, whereby an adult, contractile SMC alters its expression profile to facilitate cell proliferation, migration, and/or inflammatory cell recruitment (Shin et al. 2008) (Figure 2). Phenotypic modulation is a key event underlying atherogenesis and in-stent restenosis that involves several signaling cascades, including the Cn/NFAT pathway. Activation of Cn/NFAT signaling has been shown to induce vascular SMC proliferation and migration in response to receptor tyrosine kinase and G-protein-coupled receptor agonists, respectively (Liu, Dronadula & Rao, 2004; Yellaturu et al. 2002). Cn/NFAT activity is also critical for vessel wall assembly (Graef et al. 2001). Cyclosporin A (CsA) and the VIVIT peptide are commonly used Cn and NFAT inhibitors, respectively (Figure 1). A third pharmacological compound, A-285222, also inhibits Cn/NFAT signaling (Lee et al. 2010; Nilsson et al. 2007). Inhibition of Cn/NFAT signaling through use of either CsA or A-285222 attenuates Cn/NFAT-mediated SMC migration and proliferation in vitro (unpublished, Figure 1). Previous literature also shows that blocking Cn/NFAT signaling in vivo significantly inhibits vascular-injury-induced neointima formation (Liu et al. 2005), supporting the notion that Cn/NFAT signaling is intimately involved in the smooth muscle response to vascular injury. While NFAT-dependent gene regulation has been widely studied in lymphocytes, cardiac and skeletal muscle, the lack of known NFAT target genes in SMCs limits our understanding of Cn/NFAT signaling in vascular remodeling.

Fig. 2. The interplay between SMC phenotypic modulation and Cn/NFAT signaling in vascular disease.
4.2 Identification of DSCR1 using integrative genomics

We recently developed an unbiased, top-down, integrative genomics approach to determine downstream targets of Cn/NFAT activation in vascular SMCs (Lee et al. 2010). In brief, whole-genome expression data sets were analyzed to identify differentially upregulated genes in human, mouse, and rat SMCs. Comparison between control and phenotypic modulatory stimuli identified 63 species-conserved, upregulated genes. Differentially upregulated genes were then compared against an in silico NFAT-ome (a list of gene promoters containing at least one species-conserved physical NFAT binding site), yielding 18 potential Cn/NFAT-dependent genes. Use of pharmacological Cn/NFAT inhibitors substantiated the NFAT-dependent role for COX2, a previously identified Cn/NFAT dependent gene, and revealed the Cn/NFAT-dependent property of DSCR1 in vascular SMCs (Lee et al. 2010). DSCR1 has been reported in other cell types to function as a negative feedback regulator of Cn/NFAT signaling (Figure 1). Both gain- and loss-of-function studies were conducted to determine the role of DSCR1 in vascular SMCs. Overexpression of DSCR1 resulted in decreased NFAT transcriptional activity and reduced expression of other Cn/NFAT-dependent genes, such as COX2. Conversely, knockdown of endogenous DSCR1 enhanced NFAT transcriptional activity suggesting DSCR1 also functions as a negative regulator in vascular SMCs (Lee et al. 2010). Lastly, analysis of in vivo whole-genome expression arrays found significant DSCR1 upregulation with acute vascular injury in mouse carotid arteries, regardless of strain type (Lee et al. 2010). The significant induction of DSCR1 exemplifies its functional importance and may be critical for modulating the vascular injury response. Similarly, an extra copy of the DSCR1 gene in DS patients may function in an atheroprotective manner through its ability to negatively regulate Cn/NFAT signaling. The recent study highlighting significantly less tumor growth in DSCR1-transgenic mice (Baek et al. 2009) fosters the regulatory role of DSCR1 in Cn/NFAT-mediated cell growth. It is possible DSCR1 functions in both endothelial cells and vascular SMCs as a modulator of cell proliferation, thereby providing a shared mechanism underlying tumorigenesis and atheroma formation.

4.3 Ongoing research

Several studies are currently underway in an effort to understand the functional role of DSCR1 in SMC phenotypic modulation and atherosclerotic plaque formation. DSCR1-deficient mice have since been obtained and are proving to be instrumental as we continue to elucidate the role of DSCR1 in atherogenesis. DSCR1-related family members, however, have been identified in most eukaryotic organisms. In humans, DSCR1 family members include DSCR1-like 1 (DSCR1L1/ZAKI-4/RCAN2) and DSCR1-like 2 (DSCR1L2/RCAN3) (Strippoli et al. 2000). Interestingly, DSCR1L1 mimics the inhibitory effects of DSCR1 on Cn signaling in endothelial cells and inhibits angiogenesis (Gollogly, Ryeom & Yoon, 2007). In lymphocytes, DSCR1L2 blocks nuclear NFAT translocation and inhibits NFAT-dependent cytokine gene expression (Mulero et al. 2007). Given the functional overlap between the DSCR1 family members, global DSCR1-/- mouse models may possibly exhibit compensation by DSCR1L1 and/or DSCR1L2. In addition, DSCR1 plays a critical role in each of the major cell types seen with atherogenesis and will therefore be difficult to attribute our findings as a vascular SMC-specific response. Until a SMC-specific conditional knock-out mouse study is carried out, a conservative approach must be taken when interpreting results gathered from DSCR1-null mice given the complexities surrounding
DSCR1 expression and regulation in other cell types. Nonetheless, the data gathered will provide a better understanding of DSCR1 function. Apolipoprotein E (ApoE) is critical for lipoprotein metabolism. Defects in ApoE expression can consequently increase plasma cholesterol and triglyceride levels. Hence, targeted mutagenesis of the ApoE gene in mice promotes elevated serum cholesterol levels, where combination with a high fat/cholesterol diet results in massive accumulation of cholesterol and causative atherosclerotic lesion formation. DSCR1−/−; ApoE−/− double knockout mice have been generated in an effort to study how the absence of DSCR1 affects atherosclerotic plaque formation. These double-null mice have been placed on a 20-week, high fat/cholesterol diet to ensure plaque formation, where atherosclerotic plaque size will be quantified and compared against proper control groups. Given the literature to date, we predict atherosclerotic lesion formation and size to significantly increase in DSCR1−/−; ApoE−/− double-null mice. The absence of DSCR1, a negative regulator of Cn/NFAT activity, should in theory promote SMC proliferation and infiltration into the neointima. A recent publication, however, emphasizes the dual role of DSCR1, suggesting DSCR1 is necessary for both Cn/NFAT activation and self-regulation (Liu, Busby & Molkentin, 2009). This effect has been demonstrated in cardiomyocytes and hypertrophy, an adaptive response driven by Cn and NFATc4 signaling (De Windt et al. 2001; Molkentin et al. 1998). Several groups have shown an attenuation of cardiac hypertrophy with overexpression of DSCR1 (Rothermel et al. 2001). DSCR1−/−; DSCR1L1−/− double-null mice were thus hypothesized to demonstrate significantly greater cardiac hypertrophy. DSCR1−/−; DSCR1L1−/− double-null mice, however, exhibit the reverse response – cardiac hypertrophy is impaired in response to adrenergic stimulation or exercise, similar to responses seen in calcineurin Aβ−/− mice (Sanna et al. 2006). These results suggest a basal level of DSCR1 is necessary to properly activate Cn/NFAT signaling. The DSCR1 yeast homolog, RCN1/CBP1, has also been functionally characterized as a facilitator of Cn/NFAT signaling (Kingsbury & Cunningham, 2000). The notion that DSCR1 may also activate Cn/NFAT signaling highlights the elaborate nature of this protein, suggesting that the paradoxical function of DSCR1 depends on initial protein concentrations (Shin et al. 2006). It is thus possible we may instead observe a decrease in atherosclerotic lesion formation in the DSCR1−/−; ApoE−/− double-null mice. With this in mind, we have also placed DSCR1+/−; ApoE−/− mice to observe how DSCR1 haploinsufficiency affects plaque formation. The presence of one DSCR1 allele will allow for minimal DSCR1 expression, yet also test the effects of reduced DSCR1 expression on lesion formation.

We are also performing several in vitro assays on primary aortic SMC cultures from DSCR1−/− mice to determine the consequences of DSCR1 absence on cell functionality. With our recent findings demonstrating DSCR1 as a negative regulator of Cn/NFAT signaling in vascular SMCs (Lee et al. 2010), one would hypothesize that DSCR1-null vascular SMCs to exhibit increased cell proliferation in response to phenotypic modulatory stimuli. Preliminary data, however, show a reduced proliferative response in DSCR1-null vascular SMCs when stimulated with either platelet-derived growth factor (PDGF-BB) or serum (unpublished). These initial results support the emerging dual role of DSCR1, suggesting basal levels of DSCR1 is necessary for Cn/NFAT activation. While our model cannot fully explain the almost complete absence of atheroma formation in DS patients, our results will not only help elucidate the functional role of DSCR1 in atherogenesis, but also provide insight on the effects of trisomy 21 through a single gene approach.
5. Vascular tone and Down Syndrome

Enzyme activity of endothelial nitric oxide synthase (eNOS) plays a critical role in determining vascular tone through its ability to generate nitric oxide (NO) and consequently affect vascular smooth muscle contraction. Regulation of eNOS enzymatic activity is a highly dynamic system involving several kinases and phosphatases with significant downstream effects on NO-signaling (Duran, Breslin & Sanchez, 2010). While phosphorylation of eNOS is typically associated with enzyme activation, several groups demonstrate that dephosphorylation of eNOS can also trigger eNOS activation and subsequent NO production (Harris et al. 2001; Kou, Greif & Michel, 2002; Thomas, Chen & Keaney, Jr., 2002). The Cn phosphatase has been shown to target several proteins aside from NFAT, including eNOS (Kou et al. 2002). While the absolute role of DSCR1 is unknown in the vasculature, recent literature suggests DSCR1 plays a vital role in vessel contraction. DSCR1\(^{-/-}\) mice have been reported to exhibit an attenuated vasoconstriction response with phenylephrine treatment compared to appropriate controls (Riper et al. 2008). Riper DV et al speculate that the altered vascular constriction in DSCR1\(^{-/-}\) mice may be due to Cn dysregulation, thereby facilitating excess endothelial NO production. Based on the proposed mechanism, overexpression of DSCR1 should then limit NO formation and promote vasoconstriction. As stated earlier, however, adults with DS are significantly hypotensive when compared to control groups (Morrison et al. 1996; Richards & Enver, 1979). Although the attenuated vasoconstriction response in DSCR1\(^{-/-}\) mice may contradict the hypertensive nature of DS patients, the account by Riper DV et al is the first publication to date revealing a potential role of DSCR1 in vascular tone.

It is also important to note that these observations of a weakened vasoconstriction response in DSCR1\(^{-/-}\) mice reflect those of mesenteric rather than carotid arteries. While the underlying effects of NO on smooth muscle and vascular tone may be synonymous between the differing vascular beds, vasoconstriction could be regulated through different mechanisms. The effect of vascular bed type is further exemplified by the fact that while DS patients may be significantly hypotensive, they are also at an increased risk of developing pulmonary arterial hypertension (PAH) (Cua et al. 2007). The observed increase in PAH incidence amongst DS individuals may be due to several factors such as chronic upper airway obstruction (Jacobs, Gray & Todd, 1996) and abnormal pulmonary vasculature growth (Chi, 1975). Vascular tone therefore appears to depend not only on the vascular bed of interest but also on peripheral influences. In addition, basal levels of DSCR1 may be required for proper Cn/NFAT function, as previously described. Future contractility studies in haploinsufficient DSCR1\(^{+/+}\) mice may thus provide clarity on the true role of DSCR1 in vascular tone. This study clearly demonstrates the widespread effect of DSCR1 loss, where dysregulation of Cn/NFAT activity in the endothelium alters paracrine signaling molecule production, creating invariable effects on neighboring cell types. The prevalent nature of DSCR1 prompts consideration for cell-cell interaction effects as we continue to decipher DSCR1 function in vascular disease.

6. NFAT regulation and other considerations

The importance of calcium signaling, NFATc transcriptional regulation, and ensuing downstream gene expression is increasingly evident. Adequate and controlled Cn/NFAT signaling is necessary, as dysregulation results in several vascular pathologies. Both the
versatility in DNA binding and the presence of multiple NFAT family members suggest NFAT proteins have a more extensive role than originally anticipated. A few notable features of NFAT are brought to attention below.

NFAT transcription factors bind to DNA in a rather versatile manner. The promiscuous nature of NFAT-DNA binding suggests the presence of other binding partners. The most common and well-documented binding partner of NFAT is AP-1, a transcription factor comprised of Fos- and Jun-family proteins (Rao, Luo & Hogan, 1997). Several groups have demonstrated the need for cooperative NFAT-AP1 binding for optimal target gene transcription (Hogan et al. 2003). In addition to AP-1, NFAT has been shown to interact with other transcription factors involved in cell growth and differentiation, including GATA4, MEF2, and FOXP3 (Crabtree & Olson, 2002; Wu et al. 2006). Several groups have also noted the presence of multiple NFAT binding sites in validated NFAT-target gene promoters, such as interleukin-2 (Randak et al. 1990), interleukin-4 (Chuvpilo et al. 1993), and DSCR1 (Harris, Ermak & Davies, 2005). These multiple NFAT binding domains most likely confer a synergistic effect between NFAT-containing complexes and thereby promote efficient gene transcription (Rao et al. 1997). Thus, NFAT proteins may serve as ‘coincidence detectors’ (Crabtree & Olson, 2002) that can integrate information from multiple signaling pathways to coordinate gene expression.

The ubiquitous nature of NFAT amongst various cell types and processes demonstrates the broad-range effects of NFAT activity. While functional redundancy has been noted between the different NFAT isoforms, differences in tissue distribution (Rao et al. 1997), evidence of multiple splice variants, and distinguishing phenotypes of NFAT-deficient mice suggest NFAT proteins may in fact possess unique isoform-specific functions. For example, while NFATc1 and NFATc2 share 72% sequence agreement and demonstrate functional similarities, genetic deletion for either NFATc isoform results in divergent mouse phenotypes. Whereas NFATc2−/− mice are viable and demonstrate an enhanced immune response (Duque, Fresno & Iniguez, 2005a), NFATc1−/− mice display abnormal cardiac valve development and consequent embryonic lethality (de la Pompa et al. 1998). Variations between NFAT proteins is further seen where targeted disruption of NFATc3, but not NFATc4, significantly reduces Cn transgene-induced cardiac hypertrophy (Wilkins et al. 2002). The disparate outcomes from NFATc genetic deletions as well as the ability for NFATc isoforms to compensate one another limits the use of NFATc-specific knock-out mice.

Recent data have also challenged the longstanding premise viewing NFAT as a transcriptional activator. Several groups have in fact demonstrated the dual role of NFAT as both a gene activator and silencer (Robbs et al. 2008). NFATc1 and NFATc2 have been shown to repress cyclin-dependent kinase 4 (Horsley et al. 2008) and cyclinA2 (Carvalho et al. 2007) expression, respectively. NFATc2 has also been demonstrated as a negative regulator of cyclin B1 and cyclin E in lymphocytes (Caetano et al. 2002). The nonoverlapping functions and apparent gene silencing effects of individual NFATc proteins further complicates our understanding of Cn/NFAT signaling. NFAT is clearly involved in maintaining a balance between cell quiescence and cell proliferation – the two fundamental biological mechanisms underlying tumorigenesis and atherosclerosis.

7. Conclusions
The Cn/NFAT signaling cascade is undoubtedly a major determinant of cell growth and differentiation. Regulation of Cn/NFAT signaling is a critical determinant of neoplastic and
cardiovascular risk. With DSCR1 now known as an endogenous regulator of Cn/NFAT signaling, several groups have successfully manipulated downstream gene expression and cell function by altering DSCR1 levels. The observation that DS patients exhibit significantly less tumor growth and arterial plaque formation cannot be mere coincidence, but rather evidence supporting the notion that these large-scale, vascular-related pathologies share an underlying mechanism. This is further reinforced by the fact that DSCR1 and other candidate antiangiogenic genes found on hChr21 are of growing attention. A more comprehensive analysis of hChr21-located genes may therefore provide direction as we continue to elucidate the mechanisms underlying tumorigenesis and atherosclerotic plaque formation.

8. References

Arbuzova, S., Hutchin, T. & Cuckle, H. (2002). Mitochondrial dysfunction and Down's syndrome. *Bioessays* 24(8):681-684.

Assmann, G., Schulte, H., von, E.A. & Huang, Y. (1996). High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. *Atherosclerosis* 124 Suppl:S11-S20.

Austin, M.A., Hokanson, J.E. & Edwards, K.L. (1998). Hypertriglyceridemia as a cardiovascular risk factor. *Am J Cardiol.* 81(4A):7B-12B.

Baek, K.H., Zaslavsky, A., Lynch, R.C., Britt, C., Okada, Y., Siarey, R.J., Lensch, M.W., Park, I.H., Yoon, S.S., Minami, T., Korenberg, J.R., Folkman, J., Daley, G.Q., Aird, W.C., Galdzicki, Z. & Ryeom, S. (2009). Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. *Nature* 459(7250):1126-1130.

Berenson, G.S., Srinivasan, S.R., Bao, W., Newman, W.P., III, Tracy, R.E. & Wattigney, W.A. (1998). Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. *N. Engl. J Med.* 338(23):1650-1656.

Brown, J.R. & DuBois, R.N. (2005). COX-2: a molecular target for colorectal cancer prevention. *J Clin. Oncol.* 23(12):2840-2855.

Brown, M.S. & Goldstein, J.L. (1976). Familial hypercholesterolemia: A genetic defect in the low-density lipoprotein receptor. *N. Engl. J Med.* 294(25):1386-1390.

Buchholz, M., Schatz, A., Wagner, M., Michl, P., Linhart, T., Adler, G., Gress, T.M. & Ellenrieder, V. (2006). Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. *EMBO J* 25(15):3714-3724.

Burke, W.J., Coronado, P.G., Schmitt, C.A., Gillespie, K.M. & Chung, H.D. (1994). Blood pressure regulation in Alzheimer's disease. *J Auton. Nerv. Syst.* 48(1):65-71.

Busciglio, J., Pelsman, A., Wong, C., Pigino, G., Yuan, M., Mori, H. & Yankner, B.A. (2002). Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. *Neuron* 33(5):677-688.

Busciglio, J. & Yankner, B.A. (1995). Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. *Nature* 378(6559):776-779.

Caetano, M.S., Vieira-de-Abreu, A., Teixeira, L.K., Werneck, M.B., Barcinski, M.A. & Viola, J.P. (2002). NFATC2 transcription factor regulates cell cycle progression during
lymphocyte activation: evidence of its involvement in the control of cyclin gene expression. FASEB J 16(14):1940-1942.

Capone, G., Kim, P., Jovanovich, S., Payne, L., Freund, L., Welch, K., Miller, E. & Trush, M. (2002). Evidence for increased mitochondrial superoxide production in Down syndrome. Life Sci. 70(24):2885-2895.

Capone, G.T. (2001). Down syndrome: advances in molecular biology and the neurosciences. J Dev.Behav.Pediatr. 22(1):40-59.

Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenheuvel, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W. & Nagy, A. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380(6573):435-439.

Carvalho, L.D., Teixeira, L.K., Carrossini, N., Caldeira, A.T., Ansel, K.M., Rao, A. & Viola, J.P. (2007). The NFAT1 transcription factor is a repressor of cyclin A2 gene expression. Cell Cycle 6(14):1789-1795.

Chi, T.P.L. (1975). The pulmonary vascular bed in children with Down syndrome. J Pediatr. 86(4):533-538.

Chuvpilo, S., Schomberg, C., Gerwig, R., Heinfling, A., Reeves, R., Grummt, F. & Serfling, E. (1993). Multiple closely-linked NFAT/octamer and HMG I(Y) binding sites are part of the interleukin-4 promoter. Nucleic Acids Res. 21(24):5694-5704.

Corsi, M.M., Malavazos, A.E., Passoni, D. & Licastro, F. (2005). LDL receptor expression on T lymphocytes in old patients with Down syndrome. Immun. Ageing 2(1):3.

Crabtree, G.R. & Olson, E.N. (2002). NFAT signaling: choreographing the social lives of cells. Cell 109 Suppl:S67-S79.

Cua, C.L., Blankenship, A., North, A.L., Hayes, J. & Nelin, L.D. (2007). Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates. Pediatr.Cardiol. 28(4):250-254.

de la Pompa, J.L., Timmerman, L.A., Takimoto, H., Yoshida, H., Ellia, A.J., Samper, E., Potter, J., Wakeham, A., Marengere, L., Langille, B.L., Crabtree, G.R. & Mak, T.W. (1998). Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature 392(6672):182-186.

De Windt, L.J., Lim, H.W., Bueno, O.F., Liang, Q., Delling, U., Braz, J.C., Glascoc, B.J., Kimball, T.F., del Monte, F., Hajjar, R.J. & Molkentin, J.D. (2001). Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc.Natl Acad.Sci U.S.A. 98(6):3322-3327.

DeBakey, M.E., Lawrie, G.M. & Glaeser, D.H. (1985). Patterns of atherosclerosis and their surgical significance. Ann.Surg. 201(2):115-131.

Delabar, J.M., Theophile, D., Rahmani, Z., Chettouh, Z., Blouin, J.L., Prieur, M., Noel, B. & Sinet, P.M. (1993). Molecular mapping of twenty-four features of Down syndrome on chromosome 21. Eur J Hum Genet 1(2):114-124.

Draheim, C.C., Geijer, J.R. & Dengel, D.R. (2010). Comparison of intima-media thickness of the carotid artery and cardiovascular disease risk factors in adults with versus without the Down syndrome. Am J Cardiol. 106(10):1512-1516.

Duque, J., Fresno, M. & Iniguez, M.A. (2005a). Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of cyclooxygenase-2. J Biol Chem. 280(10):8686-8693.

www.intechopen.com
Duque, J., Fresno, M. & Iniguez, M.A. (2005b). Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of cyclooxygenase-2. *J Biol Chem.* 280(10):8686-8693.

Duque, J., Fresno, M. & Iniguez, M.A. (2005c). Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of cyclooxygenase-2. *J Biol Chem.* 280(10):8686-8693.

Duran, W.N., Breslin, J.W. & Sanchez, F.A. (2010). The NO cascade, eNOS location, and microvascular permeability. *Cardiovasc. Res.* 87(2):254-261.

Egan, J.F., Benn, P.A., Zelop, C.M., Bolnick, A., Gianferrari, E. & Borgida, A.F. (2004). Down syndrome births in the United States from 1989 to 2001. *Am J Obstet. Gynecol.* 191(3):1044-1048.

Forsythe, J.A., Jiang, B.H., Iyer, N.V., Agani, F., Leung, S.W., Koos, R.D. & Semenza, G.L. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. *Mol Cell Biol* 16(9):4604-4613.

Fuentes, J.J., Genesca, L., Kingsbury, T.J., Cunningham, K.W., Perez-Riba, M., Estivill, X. & de la, L.S. (2000). DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. *Hum Mol Genet* 9(11):1681-1690.

Gollogly, L.K., Ryeom, S.W. & Yoon, S.S. (2007). Down syndrome candidate region 1-like 1 (DSCR1-L1) mimics the inhibitory effects of DSCR1 on calcineurin signaling in endothelial cells and inhibits angiogenesis. *J Surg Res* 142(1):129-136.

Gordon, T., Castelli, W.P., Hjortland, M.C., Kannel, W.B. & Dawber, T.R. (1977). High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. *Am J Med.* 62(5):707-714.

Graef, I.A., Chen, F., Chen, L., Kuo, A. & Crabtree, G.R. (2001). Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. *Cell* 105(7):863-875.

Gord, D. & Weinberg, R.A. (2000). The Hallmarks of Cancer. *Cell* 100(1):57-70.

Hardy, J. & Selkoe, D.J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 297(5580):353-356.

Harris, C.D., Ermak, G. & Davies, K.J. (2005). Multiple roles of the DSCR1 (Adapt78 or RCAN1) gene and its protein product calcipressin 1 (or RCAN1) in disease. *Cell Mol Life Sci* 62(21):2477-2486.

Harris, M.B., Ju, H., Venema, V.J., Liang, H., Zou, R., Michell, B.J., Chen, Z.P., Kemp, B.E. & Venema, R.C. (2001). Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. *J Biol Chem.* 276(19):16587-16591.

Hasle, H., Clemmensen, I.H. & Mikkelson, M. (2000). Risks of leukaemia and solid tumours in individuals with Down's syndrome. *Lancet* 355(9199):165-169.

Hattori, M., Fujiyama, A., Taylor, T.D., Watanabe, H., Yada, T., Park, H.S., Toyoda, A., Ishii, K., Totoki, Y., Choi, D.K., Groner, Y., Soeda, E., Ohki, M., Takagi, T., Sakaki, Y., Taudien, S., Blechschmidt, K., Polley, A., Menzel, U., Delabar, J., Kumpf, K., Lehmann, R., Patterson, D., Reichwald, K., Rump, A., Schillhabel, M., Schudy, A., Zimmermann, W., Rosenthal, A., Kudoh, J., Shibuya, K., Kawasaki, K., Asakawa, S., Shintani, A., Sasaki, T., Nagamine, K., Mitsuya, S., Antonarakis, S.E., Minoshima, S., Shimizu, N., Nordsieck, G., Hornischer, K., Brant, P., Scharfe, M., Schon, O., Desario, A., Reichelt, J., Kauer, G., Blocker, H., Ramser, J., Beck, A.,
Klages, S., Hennig, S., Riesselmann, L., Dagand, E., Haaf, T., Wehrmeyer, S., Borzym, K., Gardiner, K., Nizetic, D., Francis, F., Lehrach, H., Reinhardt, R. & Yaspo, M.L. (2000). The DNA sequence of human chromosome 21. *Nature* 405(6784):311-319.

Hernandez, G.L., Volpert, O.V., Iniguez, M.A., Lorenzo, E., Martinez-Martinez, S., Grau, R., Fresno, M. & Redondo, J.M. (2001). Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. *J Exp Med.* 193(5):607-620.

Hesser, B.A., Liang, X.H., Camenisch, G., Yang, S., Lewin, D.A., Scheller, R., Ferrara, N. & Gerber, H.P. (2004). Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. *Blood* 104(1):149-158.

Hogan, P.G., Chen, L., Nardone, J. & Rao, A. (2003). Transcriptional regulation by calcium, calcineurin, and NFAT. *Genes and Development* 17(18):2205-2232.

Hokanson, J.E. & Austin, M.A. (1996). Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. *J Cardiovasc Risk* 3(2):213-219.

Horsley, V., Aliprantis, A.O., Polak, L., Glimcher, L.H. & Fuchs, E. (2008). NFATc1 balances quiescence and proliferation of skin stem cells. *Cell* 132(2):299-310.

Horsley, V. & Pavlath, G.K. (2002). Nfat: ubiquitous regulator of cell differentiation and adaptation. *The Journal of Cell Biology* 156(5):771-774.

Iizuka, M., Abe, M., Shiiba, K., Sasaki, I. & Sato, Y. (2004). Down syndrome candidate region 1, a downstream target of VEGF, participates in endothelial cell migration and angiogenesis. *J.Vasc Res.* 41(4):334-344.

Iruela-Arispe, M.L., Carpio, D. & Luque, A. (2003). ADAMTS1: a matrix metalloprotease with angioinhibitory properties. *Ann.N.Y.Acad.Sci.* 995:183-190.

Ishibashi, S., Brown, M.S., Goldstein, J.L., Gerard, R.D., Hammer, R.E. & Herz, J. (1993). Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. *J Clin.Invest* 92(2):883-893.

Ishihara, K., Amano, K., Takaki, E., Ebrahim, A.S., Shimohata, A., Shibazaki, N., Inoue, I., Takaki, M., Ueda, Y., Sago, H., Epstein, C.J. & Yamakawa, K. (2009). Increased lipid peroxidation in Down's syndrome mouse models. *J Neurochem.* 110(6):1965-1976.

Jacobs, I.N., Gray, R.F. & Todd, N.W. (1996). Upper airway obstruction in children with Down syndrome. *Arch.Otolaryngol. Head Neck Surg.* 122(9):945-950.

Jauliac, S., Lopez-Rodriguez, C., Shaw, L.M., Brown, L.F., Rao, A. & Toker, A. (2002). The role of NFAT transcription factors in integrin-mediated carcinoma invasion. *Nat Cell Biol* 4(7):540-544.

Kerins, G., Petrovic, K., Bruder, M.B. & Gruman, C. (2008). Medical conditions and medication use in adults with Down syndrome: a descriptive analysis. *Downs Syndr.Res Pract.* 12(2):141-147.

Kingsbury, T.J. & Cunningham, K.W. (2000). A conserved family of calcineurin regulators. *Genes and Development* 14(13):1595-1604.

Korenberg, J.R., Chen, X.N., Schipper, R., Sun, Z., Gonsky, R., Gerwehr, S., Carpenter, N., Daumer, C., Dignan, P., Disteche, C. & . (1994). Down syndrome phenotypes: the
consequences of chromosomal imbalance. Proc. Natl. Acad. Sci. U.S.A 91(11):4997-5001.

Kou, R., Greif, D. & Michel, T. (2002). Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporin A. J Biol Chem. 277(33):29669-29673.

Landin, K., Blennow, K., Wallin, A. & Gottfries, C.G. (1993). Low blood pressure and blood glucose levels in Alzheimer’s disease. Evidence for a hypometabolic disorder? J Intern. Med. 233(4):357-363.

Lange, A.W., Molkentin, J.D. & Yutzey, K.E. (2004). DSCR1 gene expression is dependent on NFATc1 during cardiac valve formation and colocalizes with anomalous organ development in trisomy 16 mice. Developmental Biology 266(2):346-360.

Lee, M.Y., Garvey, S.M., Baras, A.S., Lemmon, J.A., Gomez, M.F., Schoppee Bortz, P.D., Daum, G., LeBoeuf, R.C. & Wamhoff, B.R. (2010). Integrative genomics identifies DSCR1 (RCAN1) as a novel NFAT-dependent mediator of phenotypic modulation in vascular smooth muscle cells. Hum Mol Genet 19(3):468-479.

Lejeune J, Gautier, M. & Turpin, R. (1959). Etude des chromosomes somatiques de neuf enfants mongoliques. Compte Rendu d’Acad Sci (248):1721-1722.

Lipsky, P.E., Brooks, P., Crofford, L.J., DuBois, R., Graham, D., Simon, L.S., van de Putte, L.B. & Abramson, S.B. (2000). Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch. Intern. Med. 160(7):913-920.

Liu, C.H., Chang, S.H., Narko, K., Trifan, O.C., Wu, M.T., Smith, E., Haudenschild, C., Lane, T.F. & Hla, T. (2001). Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 276(21):18563-18569.

Liu, Q., Busby, J.C. & Molkentin, J.D. (2009). Interaction between TAK1-TAB1-TAB2 and RCAN1-calcineurin defines a signalling nodal control point. Nat Cell Biol 11(2):154-161.

Liu, Z., Dronadula, N. & Rao, G.N. (2004). A novel role for nuclear factor of activated T cells in receptor tyrosine kinase and G protein-coupled receptor agonist-induced vascular smooth muscle cell motility. J Biol Chem 279(39):41218-41226.

Liu, Z., Zhang, C., Dronadula, N., Li, Q. & Rao, G.N. (2005). Blockade of Nuclear Factor of Activated T Cells Activation Signaling Suppresses Balloon Injury-induced Neointima Formation in a Rat Carotid Artery Model. Journal of Biological Chemistry 280(15):14700-14708.

Lusis, A.J. (2000). Atherosclerosis. Nature 407(6801):233-241.

Mendall, M.A., Patel, P., Ballam, L., Strachan, D. & Northfield, T.C. (1996). C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 312(7038):1061-1065.

Minami, T., Horiuchi, K., Miura, M., Abid, M.R., Takabe, W., Noguchi, N., Kohro, T., Ge, X., Aburatani, H., Hamakubo, T., Kodama, T. & Aird, W.C. (2004). Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. J Biol Chem 279(48):50537-50554.

Molkentin, J.D., Lu, J.R., Antos, C.L., Markham, B., Richardson, J., Robbins, J., Grant, S.R. & Olson, E.N. (1998). A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93(2):215-228.
Moller, D.E. & Kaufman, K.D. (2005). Metabolic syndrome: a clinical and molecular perspective. *Annu.Rev.Med.* 56:45-62.

Morrison, R.A., McGrath, A., Davidson, G., Brown, J.J., Murray, G.D. & Lever, A.F. (1996). Low blood pressure in Down's syndrome, A link with Alzheimer's disease? *Hypertension* 28(4):569-575.

Mukherjee, D., Nissen, S.E. & Topol, E.J. (2001). Risk of cardiovascular events associated with selective COX-2 inhibitors. *JAMA* 286(8):954-959.

Mulero, M.C., Aubareda, A., Schluter, A. & Perez-Riba, M. (2007). RCAN3, a novel calcineurin inhibitor that down-regulates NFAT-dependent cytokine gene expression. *Biochim.Biophys.Acta* 1773(3):330-341.

Murdock, J.C., Rodger, J.C., Rao, S.S., Fletcher, C.D. & Dunnigan, M.G. (1977). Down's syndrome: an atheroma-free model? *Br.Med.J* 2(6081):226-228.

Nilsson, L.M., Sun, Z.W., Nilsson, J., Nordstrom, I., Chen, Y.W., Molkentin, J.D., Wide-Svensson, D., Hellstrand, P., Lydrup, M.L. & Gomez, M.F. (2007). Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation. *AJP - Cell Physiology* 292(3):C1167-C1178.

Nishida, Y., Akaoka, I., Nishizawa, T., Maruki, M. & Maruki, K. (1977). Hyperlipidaemia in patients with Down's syndrome. *Atherosclerosis* 26(3):369-372.

Okamura, H., Aramburu, J., Garcia-Rodriguez, C., Viola, J.P., Raghavan, A., Tahiliani, M., Zhang, X., Qin, J., Hogan, P.G. & Rao, A. (2000). Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. *Mol Cell* 6(3):539-550.

Olson, L.E., Richtsmeier, J.T., Leszl, J. & Reeves, R.H. (2004). A chromosome 21 critical region does not cause specific Down syndrome phenotypes. *Science* 306(5696):687-690.

Olson, L.E., Roper, R.J., Sengstaken, C.L., Peterson, E.A., Aquino, V., Galdzicki, Z., Siarey, R., Pletnikov, M., Moran, T.H. & Reeves, R.H. (2007). Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. *Hum Mol Genet* 16(7):774-782.

Pritchard, K.A., Jr., O'Banion, M.K., Miano, J.M., Vlasic, N., Bhatia, U.G., Young, D.A. & Stemerman, M.B. (1994). Induction of cyclooxygenase-2 in rat vascular smooth muscle cells in vitro and in vivo. *Journal of Biological Chemistry* 269(11):8504-8509.

Randak, C., Brabletz, T., Hergenrother, M., Sobotta, I. & Serfling, E. (1990). Cyclosporin A suppresses the expression of the interleukin 2 gene by inhibiting the binding of lymphocyte-specific factors to the IL-2 enhancer. *EMBO J* 9(8):2529-2536.

Rao, A., Luo, C. & Hogan, P.G. (1997). Transcription factors of the NFAT family: regulation and function. *Annu.Rev Immunol* 15:707-747.

Reddy, B.S., Hirose, Y., Lubet, R., Steele, V., Kellogg, G., Paulson, S., Seibert, K. & Rao, C.V. (2000). Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. *Cancer Res.* 60(2):293-297.

Reeves, R.H. & Citron, M.P. (1994). Mouse chromosome 16. *Mamm.Genome* 5 Spec No:S229-S237.
Reeves, R.H., Irving, N.G., Moran, T.H., Wohn, A., Kitt, C., Sisodia, S.S., Schmidt, C., Bronson, R.T. & Davison, M.T. (1995). A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet 11(2):177-184.

Richards, B.W. & Enver, F. (1979). Blood pressure in Down’s syndrome. J Ment.Defic.Res. 23(2):123-135.

Riper, D.V., Jayakumar, L., Latchana, N., Bhoiwala, D., Mitchell, A.N., Valenti, J.W. & Crawford, D.R. (2008). Regulation of vascular function by RCAN1 (ADAPT78). Arch.Biochem.Biophys. 472(1):43-50.

Robbs, B.K., Cruz, A.L., Weineck, M.B., Mogpol, G.P. & Viola, J.P. (2008). Dual roles for NFAT transcription factor genes as oncogenes and tumor suppressors. Mol Cell Biol 28(23):7168-7181.

Roizen, N.J. & Patterson, D. (2003). Down's syndrome. Lancet 361(9365):1281-1289.

Rothermel, B., Vega, R.B., Yang, J., Wu, H., Bassel-Duby, R. & Williams, R.S. (2000). A Protein Encoded within the Down Syndrome Critical Region Is Enriched in Striated Muscles and Inhibits Calcineurin Signaling. Journal of Biological Chemistry 275(12):8719-8725.

Rothermel, B.A., McKinsey, T.A., Vega, R.B., Nicol, R.L., Mammen, P., Yang, J., Antos, C.L., Shelton, J.M., Bassel-Duby, R., Olson, E.N. & Williams, R.S. (2001). Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proceedings of the National Academy of Sciences 98(6):3328-3333.

Rudic, R.D., Brinster, D., Cheng, Y., Fries, S., Song, W.L., Austin, S., Coffman, T.M. & FitzGerald, G.A. (2005). COX-2-derived prostacyclin modulates vascular remodeling. Circulation Research 96(12):1240-1247.

Ryeom, S., Baek, K.H. & Zaslavsky, A. (2009). Down's syndrome: protection against cancer and the therapeutic potential of DSCR1. Future.Oncol. 5(8):1185-1188.

Sanna, B., Brandt, E.B., Kaiser, R.A., Pfluger, P., Witt, S.A., Kimball, T.R., van Rooij, E., De Windt, L.J., Rothenberg, M.E., Tschop, M.H., Benoit, S.C. & Molkentin, J.D. (2006). Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo. Proc.Natl Acad.Sci U.S.A 103(19):7327-7332.

Shin, S.Y., Choo, S.M., Kim, D., Baek, S.J., Wolkenhauer, O. & Cho, K.H. (2006). Switching feedback mechanisms realize the dual role of MCIP in the regulation of calcineurin activity. FEBS Letters 580(25):5965-5973.

Shin, S.Y., Yang, J.M., Choo, S.M., Kwon, K.S. & Cho, K.H. (2008). System-level investigation into the regulatory mechanism of the calcineurin/NFAT signaling pathway. Cellular Signalling 20(6):1117-1124.

Stoll, C., Alembik, Y., Dott, B. & Roth, M.P. (1990). Epidemiology of Down syndrome in 118, 265 consecutive births. Am J Med.Genet Suppl 7:79-83.

Strippoli, P., Lenz, L., Petrini, M., Carinci, P. & Zannotti, M. (2000). A new gene family including DSCR1 (Down Syndrome Candidate Region 1) and ZAKI-4: characterization from yeast to human and identification of DSCR1-like 2, a novel human member (DSCR1L2). Genomics 64(3):252-263.

Sugimoto, T., Haneda, M., Sawana, H., Ishikii, K., Maeda, S., Koya, D., Inoki, K., Yasuda, H., Kashiwagi, A. & Kikkawa, R. (2001). Endothelin-1 Induces Cyclooxygenase-2 Expression Via Nuclear Factor of Activated T-Cell Transcription Factor in Glomerular Mesangial Cells. Journal of the American Society of Nephrology 12(7):1359-1368.
Thomas, S.R., Chen, K. & Keaney, J.F., Jr. (2002). Hydrogen peroxide activates endothelial nitric-oxide synthase through coordinated phosphorylation and dephosphorylation via a phosphoinositide 3-kinase-dependent signaling pathway. *J Biol Chem.* 277(8):6017-6024.

Vanderlaan, P.A., Readon, C.A. & Getz, G.S. (2004). Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators. *Arteriosclerosis, Thrombosis, and Vascular Biology* 24(1):12-22.

Wilkins, B.J., De Windt, L.J., Bueno, O.F., Braz, J.C., Glascock, B.J., Kimball, T.F. & Molkentin, J.D. (2002). Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. *Mol Cell Biol* 22(21):7603-7613.

Wouters, K., Shiri-Sverdlov, R., van Gorp, P.J., van Bilsen, M. & Hofker, M.H. (2005). Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoE and LDLR mice. *Clin Chem Lab Med.* 43(5):470-479.

Wu, Y., Borde, M., Heissmeyer, V., Feuerer, M., Lapan, A.D., Stroud, J.C., Bates, D.L., Guo, L., Han, A., Ziegler, S.F., Mathis, D., Benoist, C., Chen, L. & Rao, A. (2006). FOXP3 controls regulatory T cell function through cooperation with NFAT. *Cell* 126(2):375-387.

Yang, Q., Rasmussen, S.A. & Friedman, J.M. (2002). Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. *Lancet* 359(9311):1019-1025.

Yao, Y.G. & Duh, E.J. (2004). VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis? *Biochem.Biophys.Res Commun.* 321(3):648-656.

Yellaturu, C.R., Ghosh, S.K., Rao, R.K., Jennings, L.K., Hassid, A. & Rao, G.N. (2002). A potential role for nuclear factor of activated T-cells in receptor tyrosine kinase and G-protein-coupled receptor agonist-induced cell proliferation. *Biochem.J* 368(Pt 1):183-190.

Yla-Herttuala, S., Luoma, J., Nikkari, T. & Kivimaki, T. (1989). Down's syndrome and atherosclerosis. *Atherosclerosis* 76(2-3):269-272.

Zaslavsky, A., Baek, K.H., Lynch, R.C., Short, S., Grillo, J., Folkman, J., Italiano, J.E., Jr. & Ryeom, S. (2010). Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. *Blood* 115(22):4605-4613.
This book provides a concise yet comprehensive source of current information on Down syndrome. Research workers, scientists, medical graduates and paediatricians will find it an excellent source for reference and review. This book has been divided into four sections, beginning with the Genetics and Etiology and ending with Prenatal Diagnosis and Screening. Inside, you will find state-of-the-art information on:

1. Genetics and Etiology
2. Down syndrome Model
3. Neurologic, Urologic, Dental & Allergic disorders
4. Prenatal Diagnosis and Screening

Whilst aimed primarily at research workers on Down syndrome, we hope that the appeal of this book will extend beyond the narrow confines of academic interest and be of interest to a wider audience, especially parents and relatives of Down syndrome patients.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Monica Y. Lee and Brian R. Wamhoff (2011). Down Syndrome and Vascular Disease: DSCR1 and NFAT Signaling, Genetics and Etiology of Down Syndrome, Prof. Subrata Dey (Ed.), ISBN: 978-953-307-631-7, InTech, Available from: http://www.intechopen.com/books/genetics-and-etiology-of-down-syndrome/down-syndrome-and-vascular-disease-dscr1-and-nfat-signaling
